61148-22-9

Usage

Class

Quinoxalinone compounds

Structure

Heterocyclic organic compound with a quinoxaline skeleton

Characteristic feature

Methyl group at the 8-position of the quinoxalinone ring

Potential biological activities

Anticancer and antibacterial agents

Industrial applications

Pharmaceutical or other industries (due to potential structural and functional properties imparted by the methyl group at the 8-position)

Upstream product

• 924-44-7 glyoxylic acid ethyl ester 
• 2687-25-4 3-methyl-1,2-benzenediamine 
• 570-24-1 2-Methyl-6-nitroaniline 
• 61148-20-7 2-cyano-N-(2-methyl-6-nitrophenyl)acetamide 
• 61148-21-8 2-cyano-3-hydroxy-5-methylquinoxaline 1-oxide 

Downstream Products

• 61148-40-1 2-chloro-8-methylquinoxaline 
• 877457-66-4 3-methoxy-5-quinoxalinecarboxaldehyde 

Relevant academic research and scientific papers

Antibacterial activity of quinoxalines, quinazolines, and 1,5-naphthyridines

Several phenyl substituted naphthalenes and isoquinolines have been identified as antibacterial agents that inhibit FtsZ-Zing formation. In the present study we evaluated the antibacterial of several phenyl substituted quinoxalines, quinazolines and 1,5-naphthyridines against methicillin-sensitive and methicillin-resistant Staphylococcus aureus and vancomycin-sensitive and vancomycin-resistant Enterococcus faecalis. Some of the more active compounds against S. aureus were evaluated for their effect on FtsZ protein polymerization. Further studies were also performed to assess their relative bactericidal and bacteriostatic activities. The notable differences observed between nonquaternized and quaternized quinoxaline derivatives suggest that differing mechanisms of action are associated with their antibacterial properties.

Design, synthesis, and characterization of novel tetrahydropyran-based bacterial topoisomerase inhibitors with potent anti-gram-positive activity

There is an urgent need for new antibacterial drugs that are effective against infections caused by multidrug-resistant pathogens. Novel nonfluoroquinolone inhibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) have the potential

CYCLOHEXYL OR PIPERIDINYL CARBOXAMIDE ANTIBIOTIC DERIVATIVES

The invention relates to antibiotic cyclohexyl or piperidinyl carboximide derivatives of formula (I) wherein R1 represents hydrogen, halogen, (C1-C4)alkyl, (C1-C4)alkoxy, cyano or COOR2, R2 being (C1-C4)alkyl;one or two of U, V, W and X represent(s) N and the remaining represent each CH, or, in the case of X, may also represent CRX, RX being a halogen atom;either B represents N and A represents CH2CH2 or CH(OR3)CH2, or B represents CH or C(OR4) and A represents OCH2, CH2CH(OR5), CH(OR6)CH2, CH(OR7)CH(OR8), CH═CH or CH2CH2;each of R3, R4, R5, R6, R7, and R8 represents independently hydrogen, SO3H, PO3H2, CH2OPO3H2 or COR9, R9 being either CH2CH2COOH or such that R9—COOH is naturally occurring amino acid or dimethylaminoglycine;and to salts of such compounds of formula (I).

ETHANOL OR 1,2-ETHANEDIOL CYCLOHEXYL ANTIBIOTIC DERIVATIVES

The invention relates to antibiotic ethanol or 1,2-ethanediol cyclohexyl derivatives of formula (I) wherein R1 represents (C1-C4)alkoxy; one or two of U, V, W and X represent(s) N and the remaining represent each independently CH or, in the case of V or X

CYCLOHEXYL OR PIPERIDINYL CARBOXAMIDE ANTIBIOTIC DERIVATIVES

The invention relates to antibiotic cyclohexyl or piperidinyl carboxamide derivatives of formula (I) wherein R1 represents hydrogen, halogen, (C1-C4)alkyl, (C1-C4)alkoxy, cyano or COOR2, R2 being (C1-C4)alkyl; one or two of U, V, W and X represent(s) N and the remaining represent each CH, or, in the case of X, may also represent CRx, Rx being a halogen atom; either B represents N and A represents CH2CH2 or CH(OR3)CH2, or B represents CH or C(OR4) and A represents OCH2, CH2CH(OR5), CH(OR6)CH2, CH(OR7)CH(OR8), CH=CH or CH2CH2; each of R3, R4, R5, R6, R7 and R8 represents independently hydrogen, SO3H, PO3H2, CH2OPO3H2 or COR9, R9 being either CH2CH2COOH or such that R9-COOH is a naturally occurring amino acid or dimethylaminoglycine; and to salts of such compounds of formula (I).

New Piperidine Antibiotics

The invention relates to novel, antibacterially active piperidine derivatives of the formula wherein one of U and V represents N, the other represents N or CH; M represents CH2CH2, CH═CH, CH(OH)CH(OH), CH(OH)CH2, CH(NHsub

ANTIBIOTIC COMPOUNDS

The invention relates to selected antibiotics of formula (Al) wherein R1 represents alkyl, alkoxy, haloalkoxy, halogen or cyano; one or two of U, V, W and X represent(s) N, the remaining represent CH, or, in case of U, V and/or W, may also repr

NEW PIPERIDINE ANTIBIOTICS

The invention relates to novel, antibacterially active piperidine derivatives of the formula (I) wherein one of U and V represents N, the other represents N or CH; M represents CH2CH2, CH=CH, CH(OH)CH(OH), CH(OH)CH2, CH(NH

NOVEL COMPOUNDS HAVING AN ANTI-BACTERIAL ACTIVITY

The present invention describes novel anti-bacterial compounds of formula (I). These compounds are, amongst others, of interest as inhibitors of DNA gyrase.

4,5-Dihydrotetrazolo(1,5-A)quinoxalines

A class of new 4,5-dihydrotetrazolo[1,5-a]quinoxalines are useful for protecting plants from foliar phytopathogens.